# Snipr Biome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/snipr-biome-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.sniprbiome.com
- Total disclosed funding: $91M
- Latest round: Series B (Jul 7, 2025)
- Investors on record: 6

## About

Based in Copenhagen, Denmark, and co-founded by Christian Grøndahl (CEO), Morten O. A. Sommer (Chair of Research), and Jasper Clube (Chief Intellectual Property Officer) in 2011, Snipr Biome Aps operates as a biotechnology company that develops therapeutics that use CRISPR/Cas technology to selectively eradicate target bacteria. In July 2025, Snipr Biome Aps raised EUR 35 million in series B funding from SPRIND, Cystic Fibrosis Foundation, Lundbeckfond Ventures, Wellington Partners, North-East Venture. The company develops therapies for challenging conditions by harnessing CRISPR technology to selectively target and eliminate harmful bacteria while preserving beneficial microbiota. This approach aims to address complex diseases influenced by the human microbiome, such as inflammatory bowel disease, multi-drug resistant or difficult-to-treat infections, and cancer. Snipr Biome's pipeline includes SNIPR001-Oral, for prevention of bloodstream infection, SNIPR-IV, for sepsis kidney transplant patients, SNIPR T2D/Obesity for treating leaking gut, etc. Snipr Biome Aps will use the August 2025 funding to accelerate the development of a CRISPR-based microbial drug for eliminating antibiotic resistance genes present in humans and support the clinical advancement of its SNIPR001 CRISPR-based product for patients with hematologic cancer.

## Funding rounds

- Series B, Jul 7, 2025, $41M — Wellington Partners, Lundbeckfond Ventures, Cystic Fibrosis Foundation, North-East Venture, SPRIND
- Series A, Mar 11, 2019, $50M — Wellington Partners, EQT Life Sciences, Lundbeckfond Ventures, North-East Venture

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- North-East Venture (https://capitalatlas.ai/funds/north-east-venture) — Series A, Series B
- Cystic Fibrosis Foundation — Series B
- SPRIND — Series B